Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02562755 · ClinicalTrials.gov registry record · Phase 3
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
A Phase 3 study, sponsored by SillaJen.
- Completed
- Registry status
- Phase 3
- Development phase
- 459
- Enrollment target
NCT02562755: Completed Phase 3 study, sponsored by SillaJen.
NCT02562755 is a Phase 3 study that has completed, run by SillaJen. The registered enrollment target is 459 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02562755, a Phase 3 study, has completed, sponsored by SillaJen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 459 participants
- Enrollment target
Study Summary
This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
Primary Outcome
Percentage of participants who showed overall response during their participation in the study. Per Modified Response Evaluation Criteria In Solid Tumors Criteria (mRECIST) and assessed by tri-phasic contrast enhanced CT: Complete Response (CR), Disappearance of intratumoral enhancing area; Partial Response (PR), \>=30% decrease in the sum of the diameters of enhancing area; Overall Response (OR) = CR + PR.
Interventions
- DRUG Sorafenib
- BIOLOGICAL Pexastimogene Devacirepvec (Pexa Vec)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2015-10 |
| Est. Completion | 2020-07 |
| Phase | Phase 3 |
What the finished NCT02562755 record still lists
NCT02562755 is an interventional study that assigns participants to a tested intervention. The registered 459 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT02562755 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02562755 about?
NCT02562755 is a clinical study titled "Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone". This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.
What is the current status of trial NCT02562755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2015-10. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02562755?
The interventions under investigation include: Sorafenib (DRUG), Pexastimogene Devacirepvec (Pexa Vec) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02562755?
This trial is sponsored by SillaJen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02562755's enrollment target sits among peer trials
459 827th of 2000 higher than 1,174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia